eClinicalWorks and healow Announce Record Revenues Exceeding $1.3 Billion for 2026, Driven by Accelerating AI Adoption

At their 2026 National Conference, eClinicalWorks and healow said they expect to report revenues exceeding $1.3 billion for 2026. The companies cited offerings including cloud-based EHR, revenue cycle management, population health and AI-powered healthcare solutions; the provided article text gives no revenue comparison or market reaction.

Analysis

The investable signal is limited: a private vendor’s forward revenue claim does not establish growth quality, margins, cash conversion, or AI monetization. Without audited results, customer-retention data, or product-level growth, the announcement is weak evidence for repricing public healthcare-IT peers.

The more relevant second-order risk is bundling. If eClinicalWorks can use its EHR footprint to attach RCM and patient-engagement tools at competitive prices, standalone vendors could face pressure on renewals and sales cycles. That is a conditional competitive threat, not evidence of current share loss. Publicly traded Waystar and Phreesia are useful but imperfect read-throughs; their businesses and revenue drivers are not interchangeable with eClinicalWorks. Oracle is another broad healthcare-IT reference, not a clean comparable.

Near term, expect little durable impact absent independently verifiable customer or financial evidence. Over 1–3 months, watch peer commentary on pricing, retention, bookings, and implementation cycles. Over 6–18 months, the key question is whether AI features improve provider economics enough to support paid adoption, rather than becoming bundled table stakes. The thesis weakens if peers maintain guidance and retention, or if eClinicalWorks’ reported scale fails to translate into measurable adoption or profitability. There is no clear directional trade from this announcement alone.

Key Decisions for Investors

• No trade on the announcement alone; eClinicalWorks is private, and the claim provides no independently verifiable evidence of earnings or cash-flow impact.
• Add Waystar and Phreesia to a watchlist for earnings commentary on pricing, retention, bookings, and sales-cycle length; treat them as indirect read-throughs, not direct comparables.
• Revisit the competitive thesis only if customer wins/losses, audited financials, or product-level adoption data show that EHR bundling is changing RCM or patient-engagement economics.
• Treat AI messaging as a catalyst to verify, not a valuation driver: look for paid adoption and measurable workflow or provider-return outcomes before extrapolating.